Product Images Tadalafil
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Tadalafil NDC 73190-032 by Avkare, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
ab0f57c0-figure-01 - ab0f57c0 figure 01
ab0f57c0-figure-02 - ab0f57c0 figure 02
This text provides data on the mean change from baseline in meters for two groups: Placebo (N=82) and Tadalafil Tablets 40 mg (N=79). Statistical significance is indicated by the p-values displayed in the text. The difference in mean change between the two groups is likely being compared.*
ab0f57c0-figure-03 - ab0f57c0 figure 03
Description: The text provides statistical data related to a study involving subjects who were administered Tadalafil tablets and Placebo. It includes details such as the number of subjects, demographic information like age distribution and gender, and the change in distance walked measured in meters post-medication. Additionally, it includes placebo-adjusted mean change in minute walk distance and confidence intervals for specific metrics like systolic pulmonary pressure. This information appears to be part of a clinical trial evaluation for Tadalafil tablets.*
ab0f57c0-figure-04 - ab0f57c0 figure 04
This text appears to be a part of a chart or graph showing the percentage without clinical worsening over time for Tadalafil tablets 40 mg, Tadalafil tablets 20 mg, and Placebo. It also includes a scale of 0 to 150 for time to clinical worsening in days.*
20 mg 60 Tablets - ab0f57c0 figure 05
figure 1 - image 01
figure 2 - image 02
The text provides a list of coadministered drugs and their effects on the pharmacokinetics of Tadalafil. It includes CYP3A inhibitors like Ritonavir and Ketoconazole, CYP3A inducers like Rifampin, Bosentan, and H2 antagonists like nizatidine. The data shows the impact of these drugs on AUC (area under the curve) and Cmax (maximum concentration) values of Tadalafil. The values represent fold changes and 90% confidence intervals relative to Tadalafil alone. This information can be useful for healthcare professionals managing drug interactions involving Tadalafil.*
figure3 - image 03
This text provides information on drug-drug interactions involving CYP1A2, CYP2C9 substrates, and P-glycoprotein substrate diflgfl'é(fl 25 mg qd). It includes data on Cmax and AUC for Warfarin (R-warfarin) and Warfarin (S-warfarin), as well as recommendations for fold change and 90%CI. The general recommendation based on the data presented is no dose adjustment needed for the coadministration of the drugs listed. The text also includes a graph showing the change relative to the coadministered drug alone.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
